source
- Phase III trial shows tebentafusp doubles five-year survival in untreated metastatic uveal melanomaA Phase III study of tebentafusp in patients with previously untreated metastatic uveal melanoma reported that five-year overall survival was roughly twice that of the control group. The trial als…
- AVB-001 Cell Therapy Demonstrates Safety and Immune Activation in Platinum-Resistant Ovarian CancerAVB-001, an encapsulated interleukin-2 cell therapy, was evaluated in patients with platinum-resistant high-grade serous ovarian carcinoma. The study reported that the treatment was well tolerated.…onclive · 3mo agoPositive readoutPositive